Immune Abnormalities in Sporadic Inclusion Body Myositis
NCT00030212 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 80
Last updated 2017-07-02
Summary
This study will examine the abnormal immune response in patients with sporadic inclusion body myositis (s-IBM)-the most common inflammatory muscle disease in people over the age of 50. s-IBM progresses steadily and may lead to severe weakness and wasting of arm and leg muscles. Patients may become unable to perform daily living activities and be confined to wheelchairs. s-IBM is thought to be an autoimmune disease, in which the body's own immune system attacks healthy muscles. This study will explore the causes of the muscle tissue inflammation that is responsible for destruction of muscle fibers and weakness in this disease. Information from the study may help in the development of an effective treatment for this disease.
Patients with s-IBM may be eligible for this study. Those who are unable to travel or who have severe cardiovascular, renal or other end-stage organ disease will be excluded. Candidates will be screened for eligibility with a medical history and physical and neurological examinations.
Participants will be seen at the NIH Clinical Center every six months over a 12-month period (visits at enrollment, 6 months and 12 months) either on an inpatient or outpatient basis, depending on their disease severity. Each 2- to 3-day visit will involve the following tests and evaluations:
* Blood samples for routine laboratory tests are collected at every visit. Additional blood for research studies is collected at 12 months.
* Quantitative muscle strength testing is done at every visit. The patient pulls against straps connected to dynamometers (devices that measure muscle power) to evaluate strength of the main muscle groups in the arms and legs.
* Lymphapheresis is done at enrollment and at 12 months. This is a procedure for collecting quantities of lymphocytes (white blood cells that are an important part of the immune system). Blood is collected through a needle placed in an arm vein and circulated through a machine that spins it, separating it into its components. The lymphocytes are removed and the rest of the blood (red cells, platelets and plasma) is returned to the body through the same needle or another needle placed in the other arm.
* Electrophysiologic studies (electromyography and nerve conduction testing) are done at enrollment and 12 months. Electromyography evaluates the electrical activity of muscles. A small needle is inserted into the muscle and the patient is asked to relax or to contract the muscle. For nerve conduction testing, nerves are stimulated by electrodes (small wires taped to the skin over the muscle).
* Muscle biopsy is done at enrollment and 12 months. A sample of muscle tissue (about the size of a lima bean) from an arm or leg is surgically removed to confirm the diagnosis of s-IBM and for analysis of proteins involved in the muscle inflammation process. A local anesthetic is used to numb the area before the surgery and the wound is closed with stitches.
Conditions
- Sporadic
- Inclusion Body
- Myositis
Sponsors & Collaborators
-
National Institute of Neurological Disorders and Stroke (NINDS)
lead NIH
Eligibility
- Min Age
- 25 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2002-02-04
- Completion
- 2007-12-10
Countries
- United States
Study Locations
More Related Trials
-
Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy
NCT07103746 ·Status: RECRUITING ·Phase: PHASE2
-
Lithium in Inclusion Body Myositis (IBM)
NCT00917956 ·Status: COMPLETED
-
Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis
NCT01423110 ·Status: COMPLETED ·Phase: PHASE2
-
Intravenous Immune Globulin to Treat Hereditary Inclusion Body Myopathy
NCT00195637 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients
NCT01925209 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Long-term Extension Study of Ulviprubart (ABC008) in Subjects With Inclusion Body Myositis
NCT06450886 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3
-
Intravenousimmunoglobulin (IVIg) for the Treatment of Inflammatory Myopathies
NCT00001261 ·Status: COMPLETED ·Phase: PHASE2
-
Arimoclomol in Sporadic Inclusion Body Myositis
NCT00769860 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Adult Autoimmune Myopathies (MAIA)
NCT04792931 ·Status: RECRUITING ·Phase: NA
-
Molecular Profile of the Evolution of Inclusion Body Myositis
NCT03299335 ·Status: COMPLETED ·Phase: NA
-
Double-blind, Randomized, Placebo-controlled Trial of Etanercept for 12 Months in Subjects With Inclusion Body Myositis
NCT00802815 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis
NCT02250443 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Belimumab in Idiopathic Inflammatory Myositis
NCT02347891 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM)
NCT00106184 ·Status: COMPLETED ·Phase: PHASE2
-
Phase III Trial of Sirolimus in IBM
NCT04789070 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Phase 1 Study of ABC008 in Ascending (Single Ascending Dose/Multiple Ascending Dose) Study in Patients With (IBM)
NCT04659031 ·Status: COMPLETED ·Phase: PHASE1
-
An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203
NCT02573467 ·Status: COMPLETED ·Phase: PHASE3
-
Investigating Genes in Patients With Polymyositis and Dermatomyositis
NCT01171573 ·Status: ACTIVE_NOT_RECRUITING
-
Safety and Efficacy of REGN2477+REGN1033 in Patients With Sporadic Inclusion Body Myositis
NCT03710941 ·Status: WITHDRAWN ·Phase: PHASE2
-
Study of Arimoclomol in Inclusion Body Myositis (IBM)
NCT02753530 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Imvotamab in Active, Refractory Idiopathic Inflammatory Myopathies
NCT06524687 ·Status: TERMINATED ·Phase: PHASE1
-
A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies
NCT05379634 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Rituximab to Treat Neuropathy With Anti-MAG Antibodies
NCT00050245 ·Status: COMPLETED ·Phase: PHASE2
-
InertiaLocoGraphy as a Biomarker of Immunoglobulin Therapy Efficacy in Chronic Inflammatory Demyelinating Polyradiculoneuropathy
NCT04529291 ·Status: WITHDRAWN ·Phase: NA
-
Treatment With TNF Blockade, Infliximab, in Patients With Myositis
NCT00443222 ·Status: COMPLETED ·Phase: PHASE2/PHASE3